FOLH1 and prostate carcinoma: Radionuclide-therapy using 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands is an established treatment option for patients with PSMA-positive metastatic castration-resistant prostate cancer after previous medical therapy [1–3].